COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi

Show other versions (1)

Giriş: COVID-19 şu anda küresel sağlık için büyük bir tehdittir. Bununlabirlikte, tedavisi için spesifik bir antiviral ajan mevcut değildir. Buçalışmada; Favipiravir (FPV) ve Lopinavir/Ritonavir (LPV / RTV) ile tedavi edilen hastalarda tedavinin klinik etkinliğinin ve ilaç yan etkilerinin değerlendi...

Full description

Bibliographic Details
Main Authors:	Esma Eroğlu, Arzu Tarakçı, Fatma Çölkesen, Mihriban Şengöz, Fatma Kacar, Şule Özdemir
Format:	Article
Language:	English
Published:	Rabia Yılmaz 2020-12-01
Series:	Journal of Contemporary Medicine
Subjects:	covid-19 favipravir lopinavir/ritonavir
Online Access:	https://dergipark.org.tr/tr/download/article-file/1161377

Similar Items

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
by: Adewale Bayode Owa, et al.
Published: (2020-10-01)

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children
by: Nils von Hentig, et al.
Published: (2021-05-01)

Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
by: Simone Meini, et al.
Published: (2020-06-01)

Efficacy of lopinavir/ritonavir plus interferon beta compared to hydroxychloroquine in the treatment of COVID-19: A retrospective observational study
by: Motahareh Amirizadeh, et al.
Published: (2023-01-01)

Retrospective analysis of severe COVID-19 pneumonia patients treated with lopinavir/ritonavir: A comparison with survivor and non-survivor patients
by: Omer Ayten, et al.
Published: (2020-12-01)

The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
by: V. B. Denisenko,, et al.
Published: (2018-12-01)

Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital
by: Natsuda Aumpan, et al.
Published: (2021-09-01)

Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
by: Alexander M. Kaizer, et al.
Published: (2023-03-01)

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
by: Tatsuhiko Wada, et al.
Published: (2020-05-01)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018-06-01)

Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
by: Saad Alhumaid, et al.
Published: (2020-11-01)

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
by: Ayşe BATIREL, et al.
Published: (2021-12-01)

Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials
by: Tejas K. Patel, et al.
Published: (2021-06-01)

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
by: B. K. Romanov
Published: (2020-09-01)

Evaluating the Effects of Umifenovir Compared to Lopinavir/Ritonavir in the Management of Patients with COVID-19: A Randomized Controlled Trial
by: Farzaneh Dastan, et al.
Published: (2022-12-01)

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19
by: Mario Karolyi, et al.
Published: (2021-07-01)

Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
by: Min Joo Choi, et al.
Published: (2021-01-01)

Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients
by: Sahar K. Hegazy, et al.
Published: (2023-06-01)

Simultaneous determination of plasma lopinavir and ritonavir by chemometrics-assisted spectrophotometry and comparison with HPLC method
by: Chutima Matayatsuk Phechkrajang
Published: (2013-06-01)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
by: Qomara WF, et al.
Published: (2021-11-01)

Comparison of the Efficacy of Sofosbuvir and Kaletra on the Outcome of COVID-19. Is Sofosbuvir A Potential Treatment For COVID-19?
by: Shahnaz Sali, et al.
Published: (2020-12-01)

Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study
by: Xi Liu, et al.
Published: (2020-07-01)

Atazanavir efficacy in covid-19: A retrospective protease inhibitors comparative study 2020
by: Ahmad Alikhani, et al.
Published: (2022-01-01)

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
by: Ji-Won Kim, et al.
Published: (2021-03-01)

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
by: Chien-Yu Cheng, et al.
Published: (2020-06-01)

The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial
by: Justin T. Denholm, et al.
Published: (2020-07-01)

Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection
by: Irin Tanaudommongkon, et al.
Published: (2021-06-01)

Melatonin and alpha lipoic acid restore electrolytes and kidney morphology of lopinavir/ritonavir-treated rats
by: Elias Adikwu, et al.
Published: (2020-01-01)

Severe bradyarrhythmia requiring temporary pacemaker in a COVID-19 patient receiving lopinavir/ritonavir treatment: a case report
by: Zhenisgul Sh. Tlegenova, et al.
Published: (2020-06-01)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
by: Yin-Qiu Huang, et al.
Published: (2020-07-01)

Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
by: Mehdi Hassaniazad, et al.
Published: (2020-10-01)

Role of Kaletra (combination of lopinavir and ritonavir) in the treatment of COVID-19 virus infection; an issue related to kidney transplant patients – A review study on current knowledge
by: Seyed Seifollah Beladi Mousavi, et al.
Published: (2020-07-01)

Clinical evaluation of selected Pharmacological Treatments used for Coronavirus (COVID-19) pandemic
by: hasan mohammed altemimy
Published: (2020-06-01)

High Prevalence of Potential Drug-Drug Interactions Among Patients Treated with Off-label Therapies for COVID-19
by: Allan Ramos-Esquivel, et al.
Published: (2022-06-01)

Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
by: Shahamah Jomah, et al.
Published: (2020-09-01)

Pharmacological management of COVID-19
by: Veena Raghunathan, et al.
Published: (2020-01-01)

Clinical and Immunological Outcomes after Initiation of Second Line Antiretroviral Therapy in People Living with HIV
by: BASAVAPRABHU ACHAPPA, et al.
Published: (2019-01-01)

Potential clinically significant life-threatening drug–drug interactions of lopinavir and ritonavir used in the treatment of COVID-19
by: Mohitosh Biswas, et al.
Published: (2020-01-01)